150 related articles for article (PubMed ID: 30006927)
21. Insights from HuR biology point to potential improvement for second-line ovarian cancer therapy.
Huang YH; Peng W; Furuuchi N; DuHadaway JB; Jimbo M; Pirritano A; Dunton CJ; Daum GS; Leiby BE; Brody JR; Sawicki JA
Oncotarget; 2016 Apr; 7(16):21812-24. PubMed ID: 26943573
[TBL] [Abstract][Full Text] [Related]
22. Multiple blocks in the engagement of oxidative phosphorylation in putative ovarian cancer stem cells: implication for maintenance therapy with glycolysis inhibitors.
Alvero AB; Montagna MK; Sumi NJ; Joo WD; Graham E; Mor G
Oncotarget; 2014 Sep; 5(18):8703-15. PubMed ID: 25237928
[TBL] [Abstract][Full Text] [Related]
23. Expression of putative stem marker nestin and CD133 in advanced serous ovarian cancer.
Qin Q; Sun Y; Fei M; Zhang J; Jia Y; Gu M; Xia R; Chen S; Deng A
Neoplasma; 2012; 59(3):310-5. PubMed ID: 22296500
[TBL] [Abstract][Full Text] [Related]
24. Isolation and characterization of cancer stem cells from high-grade serous ovarian carcinomas.
He QZ; Luo XZ; Wang K; Zhou Q; Ao H; Yang Y; Li SX; Li Y; Zhu HT; Duan T
Cell Physiol Biochem; 2014; 33(1):173-84. PubMed ID: 24504111
[TBL] [Abstract][Full Text] [Related]
25. Comprehensive in situ analysis of ALDH1 and SOX2 reveals increased expression of stem cell markers in high-grade serous carcinomas compared to low-grade serous carcinomas and atypical proliferative serous tumors.
Fischer AK; Pham DL; Bösmüller H; Lengerke C; Wagner P; Bachmann C; Beschorner C; Perner S; Kommoss S; Fend F; Staebler A
Virchows Arch; 2019 Oct; 475(4):479-488. PubMed ID: 31451895
[TBL] [Abstract][Full Text] [Related]
26. Expression of Bcl-xL in ovarian carcinoma is associated with chemoresistance and recurrent disease.
Williams J; Lucas PC; Griffith KA; Choi M; Fogoros S; Hu YY; Liu JR
Gynecol Oncol; 2005 Feb; 96(2):287-95. PubMed ID: 15661210
[TBL] [Abstract][Full Text] [Related]
27. Expression of B7-H4 and IDO1 is associated with drug resistance and poor prognosis in high-grade serous ovarian carcinomas.
Niu N; Shen W; Zhong Y; Bast RC; Jazaeri A; Sood AK; Liu J
Hum Pathol; 2021 Jul; 113():20-27. PubMed ID: 33887301
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of the JAK2/STAT3 pathway in ovarian cancer results in the loss of cancer stem cell-like characteristics and a reduced tumor burden.
Abubaker K; Luwor RB; Zhu H; McNally O; Quinn MA; Burns CJ; Thompson EW; Findlay JK; Ahmed N
BMC Cancer; 2014 May; 14():317. PubMed ID: 24886434
[TBL] [Abstract][Full Text] [Related]
29. Is sphere assay useful for the identification of cancer initiating cells of the ovary?
Martínez-Serrano MJ; Caballero-Baños M; Vilella R; Vidal L; Pahisa J; Martínez-Roman S
Int J Gynecol Cancer; 2015 Jan; 25(1):12-7. PubMed ID: 25365589
[TBL] [Abstract][Full Text] [Related]
30. Downregulation of MYPT1 increases tumor resistance in ovarian cancer by targeting the Hippo pathway and increasing the stemness.
Muñoz-Galván S; Felipe-Abrio B; Verdugo-Sivianes EM; Perez M; Jiménez-García MP; Suarez-Martinez E; Estevez-Garcia P; Carnero A
Mol Cancer; 2020 Jan; 19(1):7. PubMed ID: 31926547
[TBL] [Abstract][Full Text] [Related]
31. Cancer stem cells, epithelial-mesenchymal transition, and drug resistance in high-grade ovarian serous carcinoma.
Chen X; Zhang J; Zhang Z; Li H; Cheng W; Liu J
Hum Pathol; 2013 Nov; 44(11):2373-84. PubMed ID: 23850493
[TBL] [Abstract][Full Text] [Related]
32. Chromatin target of protein arginine methyltransferase regulates invasion, chemoresistance, and stemness in epithelial ovarian cancer.
Feng X; Li L; Wang L; Luo S; Bai X
Biosci Rep; 2019 Apr; 39(4):. PubMed ID: 30910850
[TBL] [Abstract][Full Text] [Related]
33. Low MAD2 expression levels associate with reduced progression-free survival in patients with high-grade serous epithelial ovarian cancer.
Furlong F; Fitzpatrick P; O'Toole S; Phelan S; McGrogan B; Maguire A; O'Grady A; Gallagher M; Prencipe M; McGoldrick A; McGettigan P; Brennan D; Sheils O; Martin C; W Kay E; O'Leary J; McCann A
J Pathol; 2012 Apr; 226(5):746-55. PubMed ID: 22069160
[TBL] [Abstract][Full Text] [Related]
34. Tubo-Ovarian Transitional Cell Carcinoma and High-grade Serous Carcinoma Show Subtly Different Immunohistochemistry Profiles.
Magrill J; Karnezis AN; Tessier-Cloutier B; Talhouk A; Kommoss S; Cochrane D; Chow C; Cheng A; Soslow R; Hauptmann S; du Bois A; Pfisterer J; Gilks CB; Huntsman DG; Kommoss F
Int J Gynecol Pathol; 2019 Nov; 38(6):552-561. PubMed ID: 30059451
[TBL] [Abstract][Full Text] [Related]
35. EZH2 activates CHK1 signaling to promote ovarian cancer chemoresistance by maintaining the properties of cancer stem cells.
Wen Y; Hou Y; Yi X; Sun S; Guo J; He X; Li T; Cai J; Wang Z
Theranostics; 2021; 11(4):1795-1813. PubMed ID: 33408782
[No Abstract] [Full Text] [Related]
36. S100B Mediates Stemness of Ovarian Cancer Stem-Like Cells Through Inhibiting p53.
Yang T; Cheng J; Yang Y; Qi W; Zhao Y; Long H; Xie R; Zhu B
Stem Cells; 2017 Feb; 35(2):325-336. PubMed ID: 27501952
[TBL] [Abstract][Full Text] [Related]
37. Tumor recurrence and drug resistance properties of side population cells in high grade ovary cancer.
Zhang QH; Dou HT; Xu P; Zhuang SC; Liu PS
Drug Res (Stuttg); 2015 Mar; 65(3):153-7. PubMed ID: 25504004
[TBL] [Abstract][Full Text] [Related]
38. A NOTCH-sensitive uPAR-regulated oncolytic adenovirus effectively suppresses pancreatic tumor growth and triggers synergistic anticancer effects with gemcitabine and nab-paclitaxel.
Mato-Berciano A; Raimondi G; Maliandi MV; Alemany R; Montoliu L; Fillat C
Oncotarget; 2017 Apr; 8(14):22700-22715. PubMed ID: 28186974
[TBL] [Abstract][Full Text] [Related]
39. A Pathological Study Using 2014 WHO Criteria Reveals Poor Prognosis of Grade 3 Ovarian Endometrioid Carcinomas.
Soyama H; Miyamoto M; Takano M; Iwahashi H; Kato K; Sakamoto T; Kuwahara M; Ishibashi H; Matuura H; Yoshikawa T; Aoyama T; Tsuda H; Furuya K
In Vivo; 2018; 32(3):597-602. PubMed ID: 29695566
[TBL] [Abstract][Full Text] [Related]
40. S100A4/Nonmuscle Myosin IIA/p53 Axis Contributes to Aggressive Features in Ovarian High-Grade Serous Carcinoma.
Hiruta A; Oguri Y; Yokoi A; Matsumoto T; Oda Y; Tomohiro M; Hashimura M; Jiang Z; Tochimoto M; Nakagawa M; Saegusa M
Am J Pathol; 2020 Nov; 190(11):2304-2316. PubMed ID: 32805233
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
